四川双马：关于控股子公司湖北健翔获得出口欧盟证明文件的公告

Core Viewpoint - Sichuan Shuangma announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. received compliance certificates from the Hubei Provincial Drug Administration, confirming that its production line for the active pharmaceutical ingredient Liraglutide meets GMP standards equivalent to those of the EU and WHO [1] Group 1 - Hubei Jianxiang received the "GMP Compliance Inspection Notification" and "Written Confirmation for Active Substances Exported to EU" from the Hubei Provincial Drug Administration [1] - The A101 production line for Liraglutide at Hubei Jianxiang was inspected and found to comply with China's GMP requirements [1] - The GMP standards met by Hubei Jianxiang are equivalent to those set by the EU, WHO, and ICH Q7 guidelines [1]